Teva Pharmaceutical Industries Limited (TEVA) Rating Reiterated by Mizuho

Teva Pharmaceutical Industries Limited (NYSE:TEVA)‘s stock had its “hold” rating reissued by Mizuho in a report issued on Monday. They presently have a $15.00 price target on the stock. Mizuho’s price target indicates a potential upside of 8.70% from the company’s previous close.

A number of other equities analysts have also recently weighed in on the stock. BTIG Research raised shares of Teva Pharmaceutical Industries Limited from a “neutral” rating to a “buy” rating and set a $24.00 price target on the stock in a research report on Monday, September 11th. TheStreet cut shares of Teva Pharmaceutical Industries Limited from a “c-” rating to a “d+” rating in a research report on Friday, August 25th. Vetr raised shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $34.17 price target on the stock in a research report on Monday, July 24th. Credit Suisse Group cut shares of Teva Pharmaceutical Industries Limited from a “neutral” rating to an “underperform” rating and reduced their price target for the stock from $25.00 to $13.00 in a research report on Wednesday, August 23rd. Finally, Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $21.00 price target (down from $28.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Thursday, August 31st. Five investment analysts have rated the stock with a sell rating, eighteen have issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $27.83.

Shares of Teva Pharmaceutical Industries Limited (TEVA) opened at 13.80 on Monday. The stock has a 50 day moving average price of $16.13 and a 200-day moving average price of $24.54. Teva Pharmaceutical Industries Limited has a 12-month low of $13.26 and a 12-month high of $44.12. The stock’s market cap is $14.02 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last released its earnings results on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The business had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. During the same period in the prior year, the firm posted $1.25 EPS. Teva Pharmaceutical Industries Limited’s revenue was up 12.9% on a year-over-year basis. Equities analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.19 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Rating Reiterated by Mizuho” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.com-unik.info/2017/11/01/teva-pharmaceutical-industries-limited-teva-rating-reiterated-by-mizuho.html.

A number of hedge funds have recently made changes to their positions in the business. Wedbush Securities Inc. increased its stake in shares of Teva Pharmaceutical Industries Limited by 34.4% in the third quarter. Wedbush Securities Inc. now owns 96,975 shares of the company’s stock worth $1,707,000 after purchasing an additional 24,828 shares in the last quarter. Menora Mivtachim Holdings LTD. grew its stake in Teva Pharmaceutical Industries Limited by 377.0% during the third quarter. Menora Mivtachim Holdings LTD. now owns 2,763,820 shares of the company’s stock valued at $48,643,000 after acquiring an additional 2,184,343 shares in the last quarter. Westpac Banking Corp purchased a new position in Teva Pharmaceutical Industries Limited during the third quarter valued at approximately $1,039,000. SOL Capital Management CO grew its stake in Teva Pharmaceutical Industries Limited by 89.9% during the third quarter. SOL Capital Management CO now owns 119,157 shares of the company’s stock valued at $2,097,000 after acquiring an additional 56,414 shares in the last quarter. Finally, Traynor Capital Management Inc. purchased a new position in Teva Pharmaceutical Industries Limited during the third quarter valued at approximately $335,000. 56.55% of the stock is currently owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

What are top analysts saying about Teva Pharmaceutical Industries Limited? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Teva Pharmaceutical Industries Limited and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit